BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38326861)

  • 1. IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion.
    Zhao L; Wang Y; Mu P; Zhang X; Qi R; Zhang Y; Zhang H; Zhu X; Dong Z; Dong Y
    Cancer Cell Int; 2024 Feb; 24(1):60. PubMed ID: 38326861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
    Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma.
    Yi K; Cui X; Liu X; Wang Y; Zhao J; Yang S; Xu C; Yang E; Xiao M; Hong B; Fang C; Kang C; Tan Y; Wang Q
    Front Immunol; 2021; 12():802795. PubMed ID: 35069587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphofructokinase 1 platelet isoform induces PD-L1 expression to promote glioblastoma immune evasion.
    Wang S; Park SH; Lim JS; Park YY; Du L; Lee JH
    Genes Genomics; 2022 Dec; 44(12):1509-1517. PubMed ID: 35917090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 6. OMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS-STING pathway to mediate GBM immune escape.
    Zhu W; Rao J; Zhang LH; Xue KM; Li L; Li JJ; Chen QZ; Fu R
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
    Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
    Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
    Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
    Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma.
    Chen CH; Chen PY; Lin YY; Feng LY; Chen SH; Chen CY; Huang YC; Huang CY; Jung SM; Chen LY; Wei KC
    J Neurosurg; 2019 Jan; 132(1):168-179. PubMed ID: 30641835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-10b-5p Impairs TET2-Mediated Inhibition of PD-L1 Transcription Thus Promoting Immune Evasion and Tumor Progression in Glioblastoma.
    Du W; Chen D; Wei K; Yu D; Gan Z; Xu G; Yao G
    Tohoku J Exp Med; 2023 Jul; 260(3):205-214. PubMed ID: 37019647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
    Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
    Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3).
    Yang CH; Yue J; Pfeffer SR; Fan M; Paulus E; Hosni-Ahmed A; Sims M; Qayyum S; Davidoff AM; Handorf CR; Pfeffer LM
    J Biol Chem; 2014 Sep; 289(36):25079-87. PubMed ID: 25059666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
    Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
    J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of Atypical Cadherin FAT1 Promotes an Immunosuppressive Tumor Microenvironment
    Irshad K; Srivastava C; Malik N; Arora M; Gupta Y; Goswami S; Sarkar C; Suri V; Mahajan S; Gupta DK; Suri A; Chattopadhyay P; Sinha S; Chosdol K
    Front Immunol; 2022; 13():813888. PubMed ID: 35720420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
    Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide promotes immune escape of GBM cells via upregulating PD-L1.
    Wang S; Yao F; Lu X; Li Q; Su Z; Lee JH; Wang C; Du L
    Am J Cancer Res; 2019; 9(6):1161-1171. PubMed ID: 31285949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients.
    Liu Y; Carlsson R; Ambjørn M; Hasan M; Badn W; Darabi A; Siesjö P; Issazadeh-Navikas S
    J Neurosci; 2013 Aug; 33(35):14231-45. PubMed ID: 23986257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
    Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
    Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction.
    Himes BT; Peterson TE; de Mooij T; Garcia LMC; Jung MY; Uhm S; Yan D; Tyson J; Jin-Lee HJ; Parney D; Abukhadra Y; Gustafson MP; Dietz AB; Johnson AJ; Dong H; Maus RL; Markovic S; Lucien F; Parney IF
    Neuro Oncol; 2020 Jul; 22(7):967-978. PubMed ID: 32080744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.